A Phase 1, Open-Label Fixed-Sequence 2-Period Study To Investigate The Effect Of Multiple Doses Of Rifampin On Palbociclib (PD-0332991) Pharmacokinetics In Healthy Volunteers

Trial Profile

A Phase 1, Open-Label Fixed-Sequence 2-Period Study To Investigate The Effect Of Multiple Doses Of Rifampin On Palbociclib (PD-0332991) Pharmacokinetics In Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2015

At a glance

  • Drugs Palbociclib (Primary) ; Rifampicin
  • Indications Breast cancer; Colorectal cancer; Glioblastoma; Liposarcoma; Mantle-cell lymphoma; Multiple myeloma; Solid tumours
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov record.
    • 16 Dec 2013 Planned End Date changed from 1 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top